AI Article Synopsis
- Methotrexate is the primary treatment for Juvenile idiopathic arthritis but may not work for all patients, especially those with polyarticular and systemic onset forms.
- The next level of treatment involves biological drugs like TNF-a blockers, but their high costs can limit accessibility for some patients.
- Leflunomide was successfully used as a treatment option in four patients who may not have responded well to Methotrexate.
Article Abstract
Methotrexate, the mainstay of treatment in Juvenile idiopathic arthritis, might not be effective in a few patients of polyarticular and systemic onset juvenile idiopathic arthritis. Use of biologicals like TNF-a blockers, the next line of preferred drugs is constrained by the high cost. We successfully used leflunomide in four patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s13312-012-0139-9 | DOI Listing |
Publication Analysis
Top Keywords
juvenile idiopathic
12
idiopathic arthritis
12
systemic onset
8
onset juvenile
8
leflunomide systemic
4
arthritis methotrexate
4
methotrexate mainstay
4
mainstay treatment
4
treatment juvenile
4
arthritis effective
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!